Walter Ogier

President and CEO, Acetylon Pharmaceuticals

Walter Ogier co-founded Harvard-affiliated Acetylon Pharmaceuticals (Boston MA, oncology and neurodegeneration) in 2008 and served as its President & CEO until its sale to Celgene in 2016. He subsequently served as founding President & CEO of Regenacy Pharmaceuticals (neuropathy and hemoglobinopathies), which was spun out of Acetylon at the time of the Celgene acquisition. In addition to continuing to serve a Director and consultant/advisor to Regenacy, Mr. Ogier currently serves as a Director of Thetis Pharmaceuticals (Branford CT, gastroenterology), a Director of privately-held Biothera Pharmaceuticals (Eagan MN, immuno-oncology), and as an advisor/mentor to several emerging biopharmaceutical companies. Mr. Ogier brings more than 30 years of biopharmaceutical / biomedical industry experience to his Board and advisory roles, including a decade with Baxter Healthcare Corporation (Deerfield IL, stem cells, immuno-oncology, cell therapy and medical devices) in product management and business development executive roles, with Aastrom Biosciences (Ann Arbor MI, cell therapy) as VP Marketing leading to a successful IPO, and in subsequent President & CEO roles with Eligix (Medford MA, stem cells and cell therapy, sold to BioTransplant), Genetix/bluebird bio (Cambridge MA, stem cell gene therapy, Nasdaq: BLUE), and Arbios Systems (Waltham, MA, liver dialysis). Mr. Ogier received a BA magna cum laude in chemistry from Williams College and an MBA from the Yale School of Management.